Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Selumetinib was the first allosteric, selective MEK inhibitor to be evaluated
in a phase 2 clinical trial in patients with metastatic melanoma. This agent produced a l4% objective response rate in patients with BRAF
mutant tumors, but failed to show a disease control advantage over temozolomide
…